



Contact: Tim Pelura, CEO, (484) 476-1396, [tipelura@immunomeinc.com](mailto:tipelura@immunomeinc.com)

## Immunome to Present at Two Major San Francisco Conferences

**Wynnewood, PA** – January 4, 2011 - **Immunome**, a discovery-stage company with a proprietary native human monoclonal antibody (N-huMAb) discovery platform, has been selected to present at two major emerging life science finance conferences in San Francisco occurring simultaneously with the **JP Morgan Healthcare Conference**, the world’s largest annual healthcare investor conference.

“We are excited and honored to have the opportunity to introduce Immunome at both of these prestigious conferences being held during the week when the biotech world comes to San Francisco”, said Tim Pelura, President and CEO of Immunome. “We believe in the extraordinary power of the human immune system to cure disease. Our technology enables us to capture natural curative antibodies of the human immune system to develop therapies for patients unable to mount an immune response. Our initial discovery programs target serious, life-threatening infections, however our platform can also create therapeutics and diagnostics for neurologic disorders, auto-immune disease, and cancer. We are working to establish relationships with companies that have proprietary targets for which they’ve been unable to generate therapeutic antibodies. Our platform has demonstrated the ability to effectively mine the rich immunome of human antibodies.”

Immunome will present on January 11th, at 11:50am during the 4th Annual **OneMedForum San Francisco 2011**, scheduled for January 11-13, 2011. The forum will be held at the Sir Francis Drake Hotel–Union Square at 450 Powell Street, San Francisco, CA.

The company also will present on January 12th, at 2:45pm during the third annual **Biotech Showcase™ 2011**, scheduled for January 10–12, 2011. The Biotech Showcase will be held at the Parc 55 Wyndham–Union Square at 55 Cyril Magnin Street, San Francisco, CA.

For more information on the **Biotech Showcase 2011** visit:

<http://www.ebdgroup.com/bts/index.php>

For more information on the **OneMedForum San Francisco 2011** visit:

<http://www.onemedplace.com/forum/>

## **About Immunome**

Immunome is a discovery stage biopharmaceutical company that has created a proprietary Native Human Monoclonal Antibody (N-huMAB) platform. N-huMAbs are the exact structures created by nature and possess the natural safety and power of the human immune system. The Immunome method is an exclusive, optimized hybridoma process that produces affinity-matured IgG N-huMAbs. The process begins with small blood samples obtained from volunteer donors who are immune to pathogens of interest. B-cells from these donors are converted to stable hybridoma cells that express full-length N-huMAbs that are specific for those pathogens. The strength of the Immunome technology is its ability to capture the innate immune response to targets of interest. The Immunome method is intrinsically unbiased, so Immunome is able to obtain N-huMAbs not accessible by other antibody cloning methods. Because the Immunome hybridomas express N-huMAbs in their authentic, full-length configurations, Immunome's N-huMAbs are suitable for functional testing without modification. Immunome has captured high affinity, potent N-huMAbs in several therapeutic classes – infectious disease, neurologic illness, and biodefense. Immunome has focused its internal development efforts on life-threatening infectious diseases and continues to attract collaborations for access to its proprietary platform.

<http://www.immunomeinc.com>